Healthcare Private Placement and M&A Transactions Review Week Ending November 9, 2025

Synchron: The company raised $200 million of Series D venture funding in a deal led by Double Point Ventures on November 6, 2025. Protocol Labs, IQTalent Partners, Qatar Holding, K5 Global, XEIA Venture Partners, In-Q-Tel, T.Rx Capital, Metis Innovative, Khosla Ventures, ARCH Venture Partners, NewTech Invest, National Reconstruction Fund Corporation, Bezos Expeditions and Qatar Investment Authority also participated in the round. The company is a developer of implantable brain-computer interface devices using endovascular stent-electrode arrays that enable neural signal recording and control for paralyzed patients.

Braveheart Bio: The company raised $185 million of Series A venture funding in a deal led by OrbiMed, Forbion and Andreessen Horowitz on November 5, 2025. Enavate Sciences and Frazier Healthcare Partners also participated in the round. The company is a developer of a cardiac myosin inhibitor intended for treating cardiovascular disorders.

Hippocratic AI: The company raised $126 million of Series C venture funding in a deal led by Avenir Growth Capital on November 3, 2025, putting the company’s pre-money valuation at $3.37 billion. Universal Health Services, WellSpan Health, Premji Invest, CapitalG, General Catalyst, Andreessen Horowitz, Cincinnati Children’s Hospital Medical Center, Kleiner Perkins, John Doerr, Rick Klausner, and other undisclosed investors also participated in the round. The company is a developer of artificial intelligence-powered virtual healthcare assistants and conversational agents for patient communication, triage, and care coordination.

Tempero Bio: The company raised $76.9 million of Series B venture funding in a deal led by 8VC on November 5, 2025, putting the company’s pre-money valuation at $71 million. Aditum Bio, Khosla Ventures, Palo Santo, SymBiosis and other undisclosed investors also participated in the round. The company is a developer of therapeutics for treating and preventing substance use disorders including alcohol and opioid addiction.

Neok Bio: The company raised $75 million of Series A venture funding from ABL Bio and other undisclosed investors on November 4, 2025, putting the company’s pre-money valuation at $41.5 million. The company is a developer of oncology therapeutics and cancer immunotherapies targeting novel biological pathways to improve treatment efficacy and patient outcomes.

Sovato: The company raised $26 million of Series B venture funding in a deal led by Beringea on November 4, 2025. GS Ventures (Korea), Teladoc Health, Polaris Partners, Puma Venture Capital and Laerdal Million Lives Fund also participated in the round. The company is a developer of a comprehensive telesurgery platform designed to make remote surgery and procedural programs safe, scalable, and commercially viable for healthcare organizations.

Onchilles Pharma: The company raised $25 million of Series A venture funding from LYZZ Capital, InVivium Capital, and Kennedy Lewis Investment Management on November 7, 2025. Lincoln Park Capital, The University of Chicago Office of Investments, and other undisclosed investors also participated in the round. The company is a developer of myeloid-targeted cancer immunotherapies and novel oncology therapeutics for treating solid tumors.

VisCardia: The company raised $20.9 million of Series C venture funding from undisclosed investors on November 3, 2025, putting the company’s pre-money valuation at $161 million. The company is a developer of implantable cardiac support devices for treating heart failure and thoracic cardiovascular diseases.

Dragon Vascular: The company raised $18.9 million of Series A venture funding from undisclosed investors on November 3, 2025, putting the company’s pre-money valuation at $17.1 million. The company is a developer of endovascular medical devices and catheter-based interventions for treating neurovascular disorders and peripheral vascular diseases.

Osteal Therapeutics: The company raised $15.6 million of Series E venture funding from undisclosed investors on November 5, 2025, putting the company’s pre-money valuation at $560 million. The company is a developer of infection therapeutics designed to reduce the mortality, morbidity, and cost of care associated with musculoskeletal infections.

Microplate Dx: The company is in the process of raising GBP 10 million of venture funding on November 6, 2025. The company is a developer of a medical diagnostic device designed to reduce deaths from drug-resistant infections.

Coherence: The company raised $10 million of venture funding in a deal led by Artesian on November 4, 2025. Spacewalk VC, Blackbird Ventures, Possible Ventures, XEIA Venture Partners, Jumpspace Ventures and Topology Ventures also participated in the round. The company is a developer of minimally invasive medical implants and devices for treating chronic medical conditions.

Olli Health: The company raised $10 million of Series A venture funding in a deal led by Industry Ventures on November 3, 2025. Tau Ventures, Arkitekt Ventures, Cannage Capital, and Equitage Ventures also participated in the round. The company is a developer of artificial intelligence-powered medical coding and documentation software for home healthcare agencies and visiting nurse services.

Auxira Health: The company raised $7.8 million of venture funding from Abundant Venture Partners and other undisclosed investors on November 4, 2025. The company is a provider of virtual clinical support services including remote scribing, care coordination, and administrative assistance for medical practices.

Epalex: The company raised $5.2 million of Series B venture funding from undisclosed investors on November 9, 2025. The company is a developer of pharmaceutical therapeutics for neurological disorders and central nervous system conditions.

Bayou Surgical: The company raised $5 million of Series B venture funding from undisclosed investors on November 5, 2025, putting the company’s pre-money valuation at $24 million. The company is a developer of surgical instruments and devices for minimally invasive laparoscopic and robotic surgery procedures.

Nymbl Systems: The company raised $4 million of venture funding from undisclosed investors on November 3, 2025. The company is a developer of electronic health records and practice management software for orthotics and prosthetics providers.

Implant Preservation Devices: The company raised $3.8 million of Series 1 venture funding from undisclosed investors on November 4, 2025. The company is a developer of medical devices for preventing and treating prosthetic joint infections and fracture-related infections.

Metsera / Pfizer: The company was acquired by Pfizer for $10 billion on November 8, 2025. Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions.

Parse Biosciences / Qiagen: The company reached a definitive agreement to be acquired by Qiagen for an estimated $225 million on November 4, 2025. The company is a developer of single-cell RNA sequencing technology and combinatorial barcoding platforms for high-throughput genomic analysis without specialized instrumentation.

Baergic Bio / Axsome Therapeutics: Axsome Therapeutics reached a definitive agreement to acquire the company, a subsidiary of Avenue Therapeutics, for an estimated $81.8 million on November 6, 2025. The company is a developer of neurological therapeutics for treating epilepsy and seizure disorders.

Evoke Pharma / QOL Medical: The company reached a definitive agreement to be acquired by QOL Medical on November 4, 2025. Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases.

BioMedomics / Orasure Technologies: The company reached a definitive agreement to be acquired by Orasure Technologies for an undisclosed amount on November 5, 2025. The company is a developer of point-of-care diagnostic tests and rapid testing devices for infectious diseases and cardiac biomarkers.

DNAsimple / Joined Bio: The company was acquired by Joined Bio for an undisclosed amount on November 3, 2025. The company is a provider of DNA sample collection kits and genomic research services for clinical studies and genomics laboratories.

Firstline Clinical / DoseMe: The company was acquired by DoseMe, a subsidiary of Fairlong Capital, for an undisclosed amount on November 3, 2025. The company is a developer of a healthcare technology platform intended to provide clinical guidelines for infectious diseases.

icometrix / GE HealthCare Technologies: The company was acquired by GE HealthCare Technologies for an undisclosed amount on November 7, 2025. The company is a developer of artificial intelligence-based software designed for the analysis of brain magnetic resonance imaging images.

L2P Research / NJ Bio: The company was acquired by NJ Bio, a subsidiary of Cohance, for an undisclosed amount on November 6, 2025. The company is an operator of a clinical research and development company intended to offer preclinical, oncology and toxicology services.

Parks Medical Electronics / Vascular Technology: The company was acquired by Vascular Technology, via its financial sponsor JLL Partners, through an LBO on November 5, 2025 for an undisclosed amount. The company is a manufacturer of doppler ultrasound devices and vascular diagnostic equipment for detecting blood flow abnormalities and cardiovascular conditions.

PhantomX / Ion Beam Applications: The company was acquired by Ion Beam Applications for an undisclosed amount on November 3, 2025. The company is a developer of medical-imaging technology and validation services intended to serve the clinical imaging, radiology research, and artificial intelligence sectors.

Plas-Tech Engineering / Presspart Verwaltungs: The company reached a definitive agreement to be acquired by Presspart Verwaltungs, a subsidiary of GEMI Grundstücksbesitz und verwaltungs, for an undisclosed amount on November 4, 2025. The company is a manufacturer of prefillable syringes, drug delivery devices, and medical device components for pharmaceutical and biotechnology companies.

studyOS / Sitero: The company was acquired by Sitero for an undisclosed amount on November 3, 2025. The company is a developer of an AI-enabled clinical data management platform intended to identify and relate risks between endpoint data, safety data, and overall reliability.

Techfit Digital Surgery / Acumed: The company was acquired by Acumed, a subsidiary of Medhold Group, for an undisclosed amount on November 5, 2025. The company is a developer of a digital surgery platform designed to enhance surgical planning and patient outcomes through workflow digitization and customization.